1. Home
  2. NMM vs NEO Comparison

NMM vs NEO Comparison

Compare NMM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$91.53

Market Cap

2.2B

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$19.36

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMM
NEO
Founded
2007
2001
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Precision Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2007
2008

Fundamental Metrics

Financial Performance
Metric
NMM
NEO
Price
$91.53
$19.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
★ $85.00
$13.38
AVG Volume (30 Days)
129.3K
★ 1.9M
Earning Date
05-05-2026
04-28-2026
Dividend Yield
★ 0.34%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.57
$10.63
Revenue Next Year
$3.66
$9.73
P/E Ratio
$7.24
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.02
$7.07
52 Week High
$95.00
$20.05

Technical Indicators

Market Signals
Indicator
NMM
NEO
Relative Strength Index (RSI) 57.52 61.61
Support Level $69.21 $16.87
Resistance Level $91.96 $19.76
Average True Range (ATR) 2.11 0.83
MACD -0.67 -0.00
Stochastic Oscillator 53.94 78.03

Price Performance

Historical Comparison
NMM
NEO

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: